Summit Therapeutics' Partner Akeso Announces Topline Results From The Randomized Phase III HARMONi-GI1 Study Evaluating Ivonescimab Plus Chemotherapy Compared With Durvalumab Plus Chemotherapy As A First-line Treatment For Patients With Advanced Biliary Tract Cancer; Study Meets Key Secondary Endpoints Of PFS And ORR
Summit Therapeutics Inc. (NASDAQ:SMMT) today noted that its partner Akeso Inc. announced positive topline results from the randomized Phase III HARMONi-GI1 study (AK112-309) evaluating ivonescimab plus chemotherapy
Summit's partner tested a new cancer medicine called ivonescimab against an older medicine, and the new one showed better results in the study. When a company's partner succeeds with a medicine, it's a good sign that the company's investment could pay off, so it's worth watching how the medicine moves forward.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.